Clinical Trial Update: Mechanism of Action of Anti-IL17 Therapy in Peripheral Spondyloarthritis [Phase 3]

View source ↗

Summary

Phase 3 trial assessing the mechanism of action of an anti-IL-17 therapy in peripheral spondyloarthritis, with the study status reported as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spondyloarthropathies

Drugs mentioned

• Anti-IL-17 therapy

Snippet

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Conditions: Spondylarthropathies | Phase 3 | Status: COMPLETED